Inocras
Category: AI in Healthcare
AI-driven whole genome sequencing diagnostics company focused on precision oncology and rare disease detection. Inocras was founded in 2020. The company is led by Jehee Suh (서제희). Based in San Diego, USA (HQ); Seoul, South Korea; Hong Kong. Team size: 101-500. Total funding raised: $100M. Latest round: Series B. Key investors include IMM Investment, LoftyRock Investment, Korea Investment & Securities, DT& Investment, Woori Investment & Securities, Shinhan Securities, DSC Investment, Dunamu & Partners, InterVest, Samsung Venture Investment, Asan Foundation, SCL Group.
- Founded
- 2020
- Headquarters
- San Diego, USA (HQ); Seoul, South Korea; Hong Kong
- Team size
- 101-500
- Total funding
- $100M
Value proposition
Inocras combines whole genome sequencing (WGS) with proprietary AI-powered bioinformatics to deliver comprehensive, clinically actionable genomic insights for cancer diagnosis, treatment selection, and minimal residual disease monitoring.
Products and solutions
CancerVision™ (WGS tumor profiling for solid tumors), MRDVision™ (WGS-based minimal residual disease detection), RareVision™ (WGS for rare disease diagnosis), Cancer Genome Nexus (research platform with Broad Institute)
Unique value
Only company offering comprehensive whole-genome sequencing (not panel-based) for both somatic + germline analysis in a single test, with AI-powered interpretation delivering >99% sensitivity/PPV and 2-week turnaround time through CLIA/CAP accredited lab.
Target customer
Hospitals, oncologists, cancer researchers, pharmaceutical companies, and patients seeking comprehensive genomic profiling for cancer and rare diseases.
Industries served
Precision Oncology, Rare Disease Diagnostics, Pharmaceutical R&D, Clinical Genomics
Technology advantage
Proprietary bioinformatics platform (GINS) with AI foundation model trained on 2,882 whole cancer genomes; IP-protected technology; CLIA-certified and CAP-accredited lab; panel-free whole-genome approach captures complex mutations (SV, CNV, non-coding) missed by targeted panels; partnership with Ultima Genomics for ppmSeq™ ultra-sensitive MRD detection.
How they differentiate
Unlike competitors using targeted gene panels, Inocras uses whole-genome sequencing covering the entire genome including complex structural variants, non-coding regions, and simultaneous somatic+germline analysis — capturing >25% of cancer mutations that panel tests miss. AI foundation model trained on thousands of whole genomes provides deeper insights.
Main competitors
Guardant Health (panel-based liquid biopsy), Foundation Medicine (comprehensive genomic profiling), Tempus (AI-driven precision medicine)
Key partnerships
Broad Institute (TCGA whole-genome analysis collaboration), Ultima Genomics (ppmSeq™ technology for MRDVision), NDS Corporation (strategic investor, scalable WGS infrastructure), AimedBio (strategic investor; ADC/clinical programs integration), Samsung Medical Center, Seoul St. Mary's Hospital, KAIST (AI foundation model co-development)
Notable customers
Samsung Medical Center, Seoul St. Mary's Hospital, 100+ cancer institutions across Asia, Accent Therapeutics (pharma partner for Phase 1/2 clinical study)
Major milestones
2020: Founded as Genome Insight in South Korea, 2022: $23M Series B led by Dunamu & Partners, 2023: $23M Series B-2 led by Samsung Venture Investment, 2024: Rebranded to Inocras, 2025: Launched AI cancer foundation model trained on 2,882 whole genomes with KAIST, 2026: $31M Series B-3 oversubscribed ($100M cumulative), Partnership with Broad Institute for TCGA whole-genome analysis, Launched MRDVision with Ultima Genomics ppmSeq™ technology, Published landmark breast cancer WGS study in Nature
Growth metrics
100+ cancer institutions in Asia; thousands of patient cases; ~30 hospitals in South Korea; commercial presence in Hong Kong
Market positioning
Emerging leader in whole-genome-based precision oncology, positioned as the WGS alternative to panel-based CGP tests, with strong clinical adoption in Asia (100+ cancer institutions) and expanding into U.S. hospital market.
Geographic focus
Asia (South Korea, Hong Kong — established with 100+ cancer institutions) expanding to United States
Patents and IP
IP-protected technology and proprietary whole genome insight platform (specific patents not publicly detailed)
About Jehee Suh (서제희)
Ex-McKinsey & Company Partner (life sciences consulting); Ex-CEO Cartexell (CAR-T cell therapy); Ex-Executive Director Helixmith; Ex-Brand Manager Novartis; Wharton School MBA
Latest news about Inocras
More AI in Healthcare companies
Official website: https://inocras.com